The Food and Drug Administration has delayed a decision on GlaxoSmithKline’s vaccine for cervical cancer, according to the British drugmaker. The FDA was scheduled to announce its ruling Tuesday on whether to approve Cervarix, but a Glaxo spokeswoman said the…

Email this Article
Add to del.icio.us
Add to digg
Add to Facebook



Sponsored Topics:
Cervarix – Cervical cancer – GlaxoSmithKline – HPV vaccine – Health

See the original post here:
FDA delays ruling on Glaxo cervical cancer vaccine